About VERAXA
VERAXA is a Healthcare company based in Heidelberg (Germany) founded in 2017 by Edward A. Lemke, Christoph A. Merten, and Christine Köhler. Antibody therapeutics for cancer treatment are developed via microfluidic screening. VERAXA has raised $3.41 million across 1 funding round. VERAXA has completed 1 acquisition, including SYNIMMUNE. VERAXA offers products and services including BiTAC Technology, ADC Technology, and Functional Antibody Screening. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is VERAXA Biotech GmbH.
Company details
VERAXA was founded in 2017 in Heidelberg, Germany, within the biotechnology sector. Antibody therapeutics for oncological conditions are developed through ADC engineering and functional antibody screening. Droplet-based microfluidic screening technology is utilized, along with innovative antibody and protein conjugation methods, to generate antibodies against complex target molecules. Operations focus on advancing treatments for cancer.
- Headquarters Heidelberg, Germany
- Founders Edward A. Lemke, Christoph A. Merten, Christine Köhler
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website veraxa.com
- Social LinkedIn
- Legal Name Veraxa Biotech Gmbh
- Total Equity Funding$3.41M (USD)
in 1 rounds
- Latest Funding Round$3.41M (USD), Series B
Jun 2019
- Investments & Acquisitions
Products & Services of VERAXA
VERAXA offers a comprehensive portfolio of products and services, including BiTAC Technology, ADC Technology, and Functional Antibody Screening.
Platform for bispecific T-cell engagers in oncology treatments.
Technology for antibody-drug conjugates targeting cancer with reduced side effects.
Method for screening antibodies to enhance therapeutic development.
Funding Insights of VERAXA
VERAXA has successfully raised a total of $3.41M through 1 strategic funding round. The most recent funding activity was a Series B round of $3.41 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.41M
- Total Rounds 1
- Last Round Series B — $3.41M
- First Round $3.41M
(Jun 2019)
All 1 funding rounds of VERAXA with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $3.41M | Series B | – | – | – |
People of VERAXA
21 people are tracked at VERAXA (10 in leadership, 5 in board & advisors, 6 in team).
| Name | Role | Group |
|---|---|---|
Edward A. Lemke | Co-Founder | Leadership |
Christoph A. Merten | Co-Founder | Leadership |
Christine Köhler | Co-Founder | Leadership |
Heinz Schwer | Managing Director | Leadership |
Christoph Antz | CEO & Co-Founder | Leadership |
Lars Hufnagel | CTO | Leadership |
Michael Ruppert | Head of BD & Licensing | Leadership |
Marian Weiss | Director Microfluidics | Leadership |
Torsten Bürgermeister | CFO | Leadership |
Paul F. Sauter | Head of Chemistry RD | Leadership |
Berthold Hackl | Chairman of the Board | Board & advisors |
Norbert Windhab | Board Member | Board & advisors |
David L. Deck | Board Member | Board & advisors |
Jürgen Bauer | Board Member | Board & advisors |
Oliver R. Baumann | Board Member | Board & advisors |
Yasemin Doeger | Executive Assistant | Team |
Stephanie Haase | Scientific Assistant | Team |
Laura Perucho Aznar | Senior Scientist | Team |
Wilma Neumann | Senior Scientist | Team |
Sadat Hasan | Microfluidics Scientist | Team |
1 more people are available in the full profile.
Complete people profiles for VERAXA
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by VERAXA
VERAXA has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SYNIMMUNE.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
German, early-stage biotech developing mono- and bi-specific antibodies for cancer treatment | synimmune.de | Tubingen, Germany | 2010 | Dec 2023 | •••• |
Complete acquisition details for VERAXA
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of VERAXA
3 dated milestones of VERAXA across 6 years, from founding to its latest funding, stage changes and deals.
- Founded VERAXA is founded.
- Funding First funding round of $3.4M.
- Acquisition Acquires SYNIMMUNE.
Web traffic of VERAXA
The website of VERAXA (veraxa.com) receives about 4.2K visits a month.
- Monthly visits4.2K
▲ 37.3% vs previous month
Websites whose visitors overlap most with VERAXA. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| gerbu.de | 100% | #4,209,132 | View details | ||
| molecularhealth.com | 100% | View details | |||
| bio-pro.de | 97% | 6K | #4,456,553 | View details | |
brain-biotech-group.com | brain-biotech-group.com | 96% | – | ||
fiz-biotech.de | fiz-biotech.de | 96% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for VERAXA
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Veraxa
Complete news archive for VERAXA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VERAXA
VERAXA was founded in 2017 and raised its 1st funding round 2 years after it was founded.
VERAXA is headquartered in Heidelberg, Germany. It is registered at Heidelberg, Baden-wurttemberg, Germany.
VERAXA is a funded company, having raised a total of $3.41M across 1 funding round to date. The company's 1st funding round was a Series B of $3.41M, raised on Jun 2019.
VERAXA was founded in 2017 in Heidelberg, Germany, within the biotechnology sector. Antibody therapeutics for oncological conditions are developed through ADC engineering and functional antibody screening. Droplet-based microfluidic screening technology is utilized, along with innovative antibody and protein conjugation methods, to generate antibodies against complex target molecules. Operations focus on advancing treatments for cancer.
VERAXA offers BiTAC Technology, ADC Technology, and Functional Antibody Screening.
VERAXA has made 1 acquisition, including SYNIMMUNE.
VERAXA operates through Veraxa Biotech Gmbh.